From: Alice Jacobs Nesselrodt

From: Alice Jacobs Nesselrodt To: Alice Jacobs Nesselrodt Subject: IMDx achieves 4th FDA clearance--QIAGEN anus C difficile QS-RGQ MDx--a test for a serious healthcare-associated infection Date: Thu, 08 May 2014 16:18:52 +0000 Attachments: IMDx release_05MAY2014.pdf I hope you all is well with you. Spring has finally arrived in Boston and we have exciting news (see below) to share as IMDx achieves its first FDA clearance for QIAGEN — the QIAGEN artus C. difficile QS-RGQ MDx Kit. This is the fourth FDA clearance in less than a year for IMDx (3 FDA clearances were obtained for Abbott kits). In April, the FDA cleared the QIAGEN artus C. difficile QS-RGQ MDx Kit, developed and manufactured by IMDx, for use on the QIAGEN QlAsymphony RGQ MDx System. In addition, IMDx and QIAGEN continue to expand the pipeline for QlAsymphony SP/AS and Rotor- Gene Q Instruments. My best, Alice FDA Clears QIAGEN's artus C. difficile QS-RGQ MDx Kit, developed in partnership with IMDx; IMDx and QIAGEN Continue to Expand Pipeline for QlAsymphony SP/AS and Rotor-Gene Q Instruments Waltham, MA — In April 2014, the FDA cleared the QIAGEN artus C. difficile QS-RGQ MDx Kit, developed and manufactured IMDx, for use on the QIAGEN QlAsymphony RGQ MDx System, for use in the United States. The artus C. difficile QS-RGQ MDx Kit, which is used as an aid in diagnosis of Clostridium difficile (C. difficile) infection, was CE- marked in December 2013. The QlAsymphony RGQ MDx System was simultaneously cleared by the FDA, and provides an integrated automated sample preparation and assay setup for a full sample to result workflow solution. The artus VanR QS-RGQ Kit, another product in the healthcare-acquired infection test menu designed, developed and manufactured by IMDx for use on the QIAGEN QlAsymphony RGQ MDx System, was CE-marked in March 2014. The artus VanR QS-RGQ Kit is intended as an aid to identify, prevent, and control vancomycin-resistant colonization in patients at risk for vancomycin-resistant enterococci infection. A Premarket Notification S10(k) submission for the test is being submitted shortly to FDA for review. "The global burden of HAIs is significant, with approximately 1 in 14 hospitalized patients acquiring an infection during their stay," says Dr. Alice Nesselrodt, Chairman & CEO of IMDx. "We are pleased to aid QIAGEN in offering users of the QlAsymphony RGQ MDx System the artus C. difficile and VanR QS-RGQ Kits in order to assist in making timely, informed decisions about patient treatment to help control the spread of HAls7 Under a multi-year development and license agreement with QIAGEN, IMDx will continue to aid in expanding the QIAGEN test menu through the design, development and manufacture of kits for use on the QlAsymphony RGQ MDx System. Additional tests in the 2014 pipeline include a test for the detection of Herpes Simplex Viruses 1 and 2 in male and female genital and oral lesions and a test for the detection of Group B Streptococcus from enriched cultures taken from pregnant women. The artus VanR, HSV-1/2, and GBS QS-RGQ Kits are not available for sale in the United States or Canada. About IMDx Based in Waltham, MA, IMDx (wwwintelligentMDx.com) designs, develops and manufactures platform-agnostic, regulatory-cleared molecular diagnostic tests that enable partners to more rapidly and efficiently expand test menus. Beyond growing its portfolio of assays for infectious disease, IMDx is pursuing new targets in companion diagnostics, oncology and human genetics, as well as next generation instrument systems. IMDx facilities are ISO 13485:2003 certified and all products are developed and manufactured within a regulatory compliant (FDA QSR, CE- IVDD and cGMP) environment. EFTA00662732 Alice Jacobs Nesselrodt, M.D. Chairman 8 CEO IntelligentMDx 285 Bear Hill Road Wait" Phon Cell: Fax: ( Email. Visit u The information transmitted is intended only for the person or entity to which it is addressed and may contain confidential and/or privileged material. My review. retransmission. dissemination or other use of. or taking of any action in reliance upon, this information by persons or entities other than the intended recipient is prohibited. If you received this in error, please contact the sender* and delete the material from all computers. EFTA00662733